TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02494973
Drug: LV5FU2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
Study: NCT00418600
Drug: Hectorol® (doxercalciferol capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hectorol capsules at 1.0 times current injection dose
Study: NCT03051880
Drug: Repair Control EGF®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)
Study: NCT03051880
Drug: Cream without rhEGF
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Study: NCT03362281
Drug: amoxicillin and clarithromycin
Normalized name: omeprazole, amoxicillin and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
Study: NCT01297608
Drug: caoted suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: coated suppository with active drug
Study: NCT01297608
Drug: coated suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: coated suppository with placebo
Study: NCT00463749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl as placebo
Study: NCT00929682
Drug: Randomization between two referenced treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1.
Study: NCT02789813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once oral administration of 500mg before exposure therapy.
Study: NCT03390179
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesure of the glucose concentration
Study: NCT03615807
Drug: Antibiotic duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic duration according to the study arms
Study: NCT00711048
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, single dose
Study: NCT00711048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, single dose
Study: NCT01113320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
Study: NCT01530178
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04551898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match BGB-DXP593 administered as specified in the treatment arm
Study: NCT00973479
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
Study: NCT04012827
Drug: Apatinib Mesylate, doxorubicin, ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
Study: NCT00589953
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
Study: NCT00563953
Drug: Liposomal pegylated doxorubicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Study: NCT03665766
Drug: Cycloserine,Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01000298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid placebo medication given twice per day for 7 days
Study: NCT00003799
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003799
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01631201
Drug: Azithromycin 1 gram
Normalized name: azithromycin 1 gram ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Azithromycin 1 gram to be administered on Day 1.
Study: NCT00141648
Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
Study: NCT00879034
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
Study: NCT00879034
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
Study: NCT00973024
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
Study: NCT01208324
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01208324
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
Study: NCT01970176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Study: NCT00570778
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Study: NCT02014506
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg IV on day -3 and -2
Study: NCT00711594
Drug: BIBW 2992 MA2 40mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I step: Increased dose cohorts from low dose to MTD
Study: NCT00711594
Drug: BIBW 2992 MA2 50mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I step: Increased dose cohorts from low dose to MTD
Study: NCT00711594
Drug: BIBW 2992 MA2 20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I step: Increased dose cohorts from low dose to MTD
Study: NCT00711594
Drug: BIBW 2992 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
Study: NCT02933879
Drug: NVXT topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment
Study: NCT02611037
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
Study: NCT02933879
Drug: Placebo (Vehicle) Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vehicle) Topical
Study: NCT00232999
Drug: Nebulized IVX-0142
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02644252
Drug: Placebo 1 capsule x 3 daily until progression
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03637361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00438360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
Study: NCT01719458
Drug: (S,S)-[11C]MRB
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radioligand
Study: NCT02807389
Drug: MSC Fistula Plug
Normalized name: Cassia fistula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
Study: NCT04539613
Drug: HPFSH & HMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: . Various gonadotropin preparations
Study: NCT01231334
Drug: Clindamycin/benzoyl peroxide plus Adapalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
Study: NCT00039754
Drug: Holmium-166-DOTMP
Normalized name: holmium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01627054
Drug: AT7519M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
Study: NCT03617081
Drug: NNC0113-2023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
Study: NCT03617081
Drug: Placebo (NNC0113-2023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0174-0833 matched placebo orally.
Study: NCT00641407
Drug: NPL insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 10 IU bedtime and then titration
Study: NCT00384800
Drug: Thalidomide(THADO), Tegafur/Uracil(UFUR)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02912234
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose clarithromycin and single-dose Apixaban
Study: NCT00372619
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally or IT age based dosage
Study: NCT00405392
Drug: Ibandronate (SB743830HD)
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04325295
Drug: Recombinant FSH (rFSH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
Study: NCT02767869
Drug: Banaba
Normalized name: BANABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
Study: NCT02767869
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
Study: NCT04301934
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current standard treatment for recurrent UTIs in postmenopausal women
Study: NCT03396497
Drug: LYC-55716
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
Study: NCT01901614
Drug: Topical Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00355862
Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)
Approvals — FDA: no, EMA: no, PMDA: no
Description: center specific therapeutic regimen without mTOR inhibition
Study: NCT02191878
Drug: TKM-080301
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKM-080301 intravenous infusion
Study: NCT02742233
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment
Study: NCT02517996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
Study: NCT04128163
Drug: QL1206
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Study: NCT02526953
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study: NCT02526953
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study: NCT00149799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
Study: NCT01744067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules 3 times a day (oral administration)
Study: NCT04428255
Drug: HBM9161 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study: NCT04428255
Drug: HBM9161 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study: NCT04428255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Study: NCT00932438
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200 mg/sqm, IV infusion every two weeks
Study: NCT02833584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg x 1 tablets according to patient's body weight
Study: NCT01095991
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet bd,
Study: NCT00197418
Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04128163
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Study: NCT01455922
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 is exenatide in DUROS
Study: NCT01831466
Drug: placebo ointment (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ointment (vehicle) BID (twice daily) for 12 weeks
Study: NCT01831466
Drug: placebo ointment (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ointment (vehicle) QD (once daily) for 12 weeks
Study: NCT00482235
Drug: MK0359
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02291783
Drug: HTL0009936
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02291783
Drug: HTL0009936 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: NCT04442633
Drug: Glutamine Cap/Tab
Normalized name: GLUTAMINE CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine Capsules: One capsule three times daily on an empty stomach for one month
Study: NCT04442633
Drug: Kenacort in orabase
Normalized name: ORABASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
Study: NCT00434993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
Study: NCT02551380
Drug: FOLINORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
Study: NCT03102515
Drug: CIC
Normalized name: BaciCap
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02935790
Drug: ACY-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT00192764
Drug: high-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06291337
Drug: Inhibition of Sweet Taste by Ibuprofen Oral Rinses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Study: NCT06291337
Drug: Inhibition of Sweet Taste by Naproxen Oral Rinses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Study: NCT01503346
Drug: DaHuang GanTsao Tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.
Study: NCT03657784
Drug: P03277
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
Study: NCT03727022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Study: NCT03727022
Drug: SM04690
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Study: NCT02504931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
Study: NCT02469987
Drug: MYL-1402O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
Study: NCT00073411
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03581149
Drug: 2L polyethylene glycol/ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
Study: NCT00559104
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used in Both Arms
Study: NCT03154515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02515799
Drug: Tacholiquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Tacholiquine ®1% - 5ml